In vitro activity of doripenem against Burkholderia pseudomallei

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3115-3117

  Thamlikitkul, Visanu ^a   Trakulsomboon, Suwanna ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BURKHOLDERIA PSEUDOMALLEI; CORRELATION ANALYSIS; DRUG ACTIVITY; EPSILOMETER TEST; IN VITRO STUDY; INHIBITION ZONE DIAMETER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARAMETER; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; CARBAPENEMS; MICROBIAL SENSITIVITY TESTS;

EID: 67649969566     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00893-08     Document Type: Article

References (15)

1. Cheng, A. C., D. A. Fisher, N. M. Anstey, D. P. Stephens, S. P. Jacups, and B. J. Currie. 2004. Outcomes of patients with melioidosis treated with meropenem. Antimicrob. Agents Chemother. 48:1763-1765.
2. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Dance, D. A., V. Wuthiekanun, W. Chaowagul, Y. Suputtamongkol, and N. J. White. 1991. Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. J. Antimicrob. Chemother. 28:321-324.
4. Godfrey, A. J., S. Wong, D. A. B. Dance, W. Chaowagul, and L. E. Bryan. 1991. Pseudomonas pseudomallei resistance to β-lactam antibiotics due to alterations in the chromosomally encoded β-lactamase. Antimicrob. Agents Chemother. 35:1635-1640.
5. Inglis, T. J., F. Rodrigues, P. Rigby, R. Norton, and B. J. Currie. 2004. Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods. Antimicrob. Agents Chemother. 48:2999-3005.
6. Karunakaran, R., and S. D. Puthucheary. 2007. Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials. Scand. J. Infect. Dis. 39:858-861.
7. Nicolau, D. P. 2008. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother. 9:23-37.
8. Poulakou, G., and H. Giamarellou. 2008. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opin. Investig. Drugs 17:749-771.
9. Simpson, A. J., Y. Suputtamongkol, M. D. Smith, B. J. Angus, A. Rajanuwong, V. Wuthiekanun, P. A. Howe, A. L. Walsh, W. Chaowagul, and N. J. White. 1999. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis. 29:381-387.
10. Thibault, F. M., E. Hernandez, D. R. Vidal, M. Girardet, and J. D. Cavallo. 2004. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J. Antimicrob. Chemother. 54:1134-1138.
11. Vorachit, M., P. Chongtrakool, S. Arkomsean, and S. Boonsong. 2000. Antimicrobial resistance in Burkholderia pseudomallei. Acta Trop. 74: 139-144.
12. White, N. J., D. A. Dance, W. Chaowagul, Y. Wattanagoon, V. Wuthiekanun, and N. Pitakwatchara. 1989. Halving of mortality of severe melioidosis by ceftazidime. Lancet ii:697-701.
13. White, N. J. 2003. Melioidosis. Lancet 361:1715-1722.
14. Wuthiekanun, V., A. C. Cheng, W. Chierakul, P. Amornchai, D. Limmathurotsakul, and W. Chaowagul. 2005. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother. 55:1029-1031.
15. Wuthiekanun, V., and S. J. Peacock. 2006. Management of melioidosis. Expert Rev. Anti Infect. Ther. 4:445-455.